Conditions: Acute Coronary Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 151
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the bleeding safety (the composite endpoint of major and clinically relevant non-major bleeding) of 2 doses of apixaban (2.5 mg BID and 5.0 mg BID) or placebo in combination with standard therapy (aspirin and /or additional antiplatelet therapy) over a 24 week treatment period in selected subjects with recent (≤7 days) acute coronary syndrome.

Detailed description:
Due to withdraw of global phase 3 study (APPRAISE-2) for safety issue, B0661004 Data monitoring committee (DMC) also recommended terminating this study. Therefore, Pfizer decided to stop this study.

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Apixaban intervention 2: Apixaban intervention 3: Placebo
Intervention descriptions: intervention 1: Apixaban 2.5 mg tablet BID for 24 weeks intervention 2: Apixaban 5.0 mg tablet BID for 24 weeks intervention 3: Placebo tablet for 24 weeks

Protocol document: